Nexalin Technology’s HALO Headset Receives IRB Approval for Human Trials at UCSD
HOUSTON, TX, Feb. 18, 2025 – Nexalin Technology, Inc. (NASDAQ: NXL, NXLIW) (the “Company” or “Nexalin”), a pioneering company in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, is thrilled to announce that it has secured Institutional Review Board (IRB) approval from the University of California, San Diego (UCSD) for clinical testing of its groundbreaking HALO™ Clarity (HALO) headset in human subjects. This study is being carried out independently by UCSD.
About HALO Headset
The HALO headset is a non-invasive, wearable device that delivers targeted, low-intensity electrical currents directly to specific areas of the brain. This innovative technology utilizes DIFS to help alleviate various neurological and psychiatric conditions, including depression, anxiety, and PTSD. The device is designed to provide personalized, flexible, and convenient treatment options for patients.
Impact on Individuals
For individuals struggling with debilitating neurological and psychiatric conditions, this approval marks a significant milestone in their quest for effective and accessible treatment options. The clinical trials at UCSD will offer a chance for a larger population to experience the benefits of the HALO headset, which could potentially lead to improved quality of life, increased productivity, and overall better mental health.
Global Implications
This approval could set a new standard for the development and implementation of non-invasive neurotechnology in the healthcare sector. The potential for widespread application and adoption of such technology could revolutionize the way mental health conditions are diagnosed and treated, making care more accessible and affordable for millions of people worldwide. Additionally, this could pave the way for further advancements in neurotechnology, potentially leading to breakthroughs in the fields of neuroscience, neurology, and psychiatry.
Conclusion
Nexalin Technology’s receipt of IRB approval for human trials of the HALO headset at UCSD represents a significant step forward in the realm of neurotechnology and mental health treatment. This non-invasive, wearable device, which utilizes Deep Intracranial Frequency Stimulation, has the potential to make a profound impact on the lives of individuals suffering from neurological and psychiatric conditions. Furthermore, the global implications of this approval could lead to a paradigm shift in the diagnosis and treatment of these conditions, making care more accessible, affordable, and effective for millions of people worldwide.
- Nexalin Technology’s HALO headset receives IRB approval for human trials at UCSD
- Non-invasive, wearable device uses Deep Intracranial Frequency Stimulation (DIFS)
- Potential to alleviate various neurological and psychiatric conditions, such as depression, anxiety, and PTSD
- Could revolutionize mental health treatment and make care more accessible and affordable
